“…Pituitary hormone deficiencies, which include congenital hypopituitarism (combined pituitary hormone deficiencies), acquired hypopituitarism (secondary to trauma, surgery, chemotherapy, or radiotherapy), as well as pituitary tumors such as adenomas, result in a severe disruption of endocrine systems that could be addressed with PSC therapy ( Castinetti et al, 2011 ). Previous mouse studies demonstrated the existence of PSCs and their ability to self-renew and differentiate into all five endocrine cell types ( Andoniadou et al, 2013 ; Rizzoti et al, 2013 ), thus opening potential therapeutic avenues for human pituitary deficiencies and pituitary tumors ( Russell et al, 2018 ; Vankelecom, 2016 ). Little is known about the epigenetic landscape (chromatin changes as measured by chromatin accessibility assays) and the dynamics of human PSCs during postnatal life, which is critical information for realizing their therapeutic potential.…”